<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>3(6)</volume><submitter>Rodriguez-Calienes A</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Procedural intravenous cangrelor has been proposed as an effective platelet inhibition strategy for stenting in acute ischemic stroke. We aimed to compare the safety profile of low-dose intravenous cangrelor versus dual oral antiplatelet therapy (DAPT) loading in patients with acute cervical tandem lesions.&lt;h4>Methods&lt;/h4>We retrospectively identified cases from an international multicenter cohort who underwent intraprocedural administration of intravenous cangrelor (15 μg/kg followed by an infusion of 2 μg/kg per min) or DAPT loading during acute tandem lesions intervention. Safety outcomes included rates of symptomatic intracranial hemorrhage, parenchymal hematoma type 2, petechial hemorrhage, and in-stent thrombosis. Inverse probability of treatment weighting matching</pubmed_abstract><journal>Stroke (Hoboken, N.J.)</journal><pagination>e001020</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12778733</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Safety of Intravenous Cangrelor Versus Dual Oral Antiplatelet Loading Therapy in Endovascular Treatment of Tandem Lesions: An Observational Cohort Study.</pubmed_title><pmcid>PMC12778733</pmcid><pubmed_authors>Yoo A</pubmed_authors><pubmed_authors>Petersen N</pubmed_authors><pubmed_authors>Malik AM</pubmed_authors><pubmed_authors>Farooqui M</pubmed_authors><pubmed_authors>Jumaa M</pubmed_authors><pubmed_authors>Siegler JE</pubmed_authors><pubmed_authors>Sheth S</pubmed_authors><pubmed_authors>Abraham M</pubmed_authors><pubmed_authors>Janjua N</pubmed_authors><pubmed_authors>Hassan AE</pubmed_authors><pubmed_authors>Vivanco-Suarez J</pubmed_authors><pubmed_authors>Quispe-Orozco D</pubmed_authors><pubmed_authors>Linares G</pubmed_authors><pubmed_authors>Nguyen T</pubmed_authors><pubmed_authors>Guerrero WR</pubmed_authors><pubmed_authors>Jovin T</pubmed_authors><pubmed_authors>Ribo M</pubmed_authors><pubmed_authors>Rodriguez-Calienes A</pubmed_authors><pubmed_authors>Galecio-Castillo M</pubmed_authors><pubmed_authors>Ortega-Gutierrez S</pubmed_authors><pubmed_authors>Divani AA</pubmed_authors><pubmed_authors>Malaga M</pubmed_authors><pubmed_authors>Fifi J</pubmed_authors><pubmed_authors>Oliver M</pubmed_authors><pubmed_authors>Alhajala H</pubmed_authors></additional><is_claimable>false</is_claimable><name>Safety of Intravenous Cangrelor Versus Dual Oral Antiplatelet Loading Therapy in Endovascular Treatment of Tandem Lesions: An Observational Cohort Study.</name><description>&lt;h4>Background&lt;/h4>Procedural intravenous cangrelor has been proposed as an effective platelet inhibition strategy for stenting in acute ischemic stroke. We aimed to compare the safety profile of low-dose intravenous cangrelor versus dual oral antiplatelet therapy (DAPT) loading in patients with acute cervical tandem lesions.&lt;h4>Methods&lt;/h4>We retrospectively identified cases from an international multicenter cohort who underwent intraprocedural administration of intravenous cangrelor (15 μg/kg followed by an infusion of 2 μg/kg per min) or DAPT loading during acute tandem lesions intervention. Safety outcomes included rates of symptomatic intracranial hemorrhage, parenchymal hematoma type 2, petechial hemorrhage, and in-stent thrombosis. Inverse probability of treatment weighting matching</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Nov</publication><modification>2026-06-06T22:36:52.913Z</modification><creation>2026-06-06T03:10:48.696Z</creation></dates><accession>S-EPMC12778733</accession><cross_references><pubmed>41585048</pubmed><doi>10.1161/SVIN.123.001020</doi></cross_references></HashMap>